IL22 and colitis: In colitic mice, the administration of I3C triggers an IL-22-dependent mechanism that attenuates colonic inflammation, and prevents the microbial dysbiosis caused by colitis by increasing a subset of Gram-positive bacteria known to produce butyrate [39].